DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea · Delayed Price · Currency is KRW 5,430.00
-180.00 (-3.21%)
At close: Feb 13, 2026
DongKoo Bio & Pharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 770.31 | 2,036 | 11,812 | 6,614 | 9,327 | 9,140 |
Depreciation & Amortization | 8,874 | 7,274 | 6,028 | 5,632 | 5,054 | 4,506 |
Loss (Gain) From Sale of Assets | 0 | -5.98 | 0 | -123.89 | 1.33 | 81.62 |
Asset Writedown & Restructuring Costs | 365.56 | 665.56 | - | - | 0 | - |
Loss (Gain) From Sale of Investments | -4,003 | -7,119 | -2,077 | 8,869 | -1,090 | -1,985 |
Loss (Gain) on Equity Investments | 4,310 | 13,112 | 660.61 | -118.28 | 1,733 | -726.96 |
Stock-Based Compensation | 203.66 | 251.89 | 224.51 | - | - | - |
Provision & Write-off of Bad Debts | 56.45 | -193.35 | -52.82 | 40.44 | 241.76 | 1,370 |
Other Operating Activities | -3,005 | 2,295 | 1,697 | 331.91 | 638.04 | 1,744 |
Change in Accounts Receivable | -5,698 | 478.4 | -1,333 | -2,861 | 1,431 | 1,532 |
Change in Inventory | -14,993 | -6,632 | -12,838 | -6,686 | -1,897 | -7,192 |
Change in Accounts Payable | -1,404 | 4,389 | -3,093 | 2,715 | 2,399 | -2,040 |
Change in Other Net Operating Assets | 4,217 | 793.42 | 2,558 | 2,404 | 65.1 | 1,058 |
Operating Cash Flow | -10,306 | 17,344 | 3,585 | 16,819 | 17,903 | 7,489 |
Operating Cash Flow Growth | - | 383.75% | -78.68% | -6.05% | 139.06% | -21.23% |
Capital Expenditures | -8,270 | -21,866 | -13,845 | -4,978 | -4,266 | -5,268 |
Sale of Property, Plant & Equipment | - | 6 | 0.66 | 300.44 | 11.97 | - |
Sale (Purchase) of Intangibles | -1,818 | -3,598 | -2,034 | -6,098 | -1,137 | -192.72 |
Investment in Securities | -18,850 | -18,433 | 11,851 | -16,287 | 6,202 | -6,072 |
Other Investing Activities | 20.3 | 583.28 | -106 | 39 | -366.43 | -1,059 |
Investing Cash Flow | -30,599 | -45,033 | -5,133 | -27,014 | 463.93 | -12,564 |
Short-Term Debt Issued | - | 47,029 | 7,500 | 15,000 | 70.75 | 10,000 |
Long-Term Debt Issued | - | 9,895 | 1,447 | - | - | - |
Total Debt Issued | 75,707 | 56,924 | 8,947 | 15,000 | 70.75 | 10,000 |
Short-Term Debt Repaid | - | -13,528 | - | - | - | -6,883 |
Long-Term Debt Repaid | - | -935.5 | -1,126 | -5,966 | -742.12 | -2,536 |
Total Debt Repaid | -43,825 | -14,463 | -1,126 | -5,966 | -742.12 | -9,419 |
Net Debt Issued (Repaid) | 31,882 | 42,461 | 7,821 | 9,034 | -671.37 | 581.47 |
Repurchase of Common Stock | -408.34 | -3,408 | -79.9 | -2,995 | -1,998 | - |
Dividends Paid | -3,245 | -3,313 | -3,038 | -2,804 | -942.94 | -942.92 |
Other Financing Activities | -68.35 | 1,454 | 49 | -50 | -76.1 | 0 |
Financing Cash Flow | 28,160 | 37,194 | 4,752 | 3,185 | -3,688 | -361.45 |
Foreign Exchange Rate Adjustments | -61.29 | 154.83 | -4.74 | -33.91 | -2.27 | -23.18 |
Miscellaneous Cash Flow Adjustments | - | - | - | 0 | -0 | -0 |
Net Cash Flow | -12,807 | 9,660 | 3,199 | -7,043 | 14,676 | -5,460 |
Free Cash Flow | -18,577 | -4,522 | -10,260 | 11,841 | 13,637 | 2,221 |
Free Cash Flow Growth | - | - | - | -13.16% | 514.06% | -74.46% |
Free Cash Flow Margin | -7.79% | -1.81% | -4.76% | 6.07% | 8.79% | 1.59% |
Free Cash Flow Per Share | -668.75 | -165.59 | -371.44 | 426.63 | 482.57 | 78.50 |
Cash Interest Paid | 3,502 | 2,828 | 1,672 | 902.19 | 362.76 | 401.35 |
Cash Income Tax Paid | 3,787 | 2,775 | 4,104 | 3,076 | 1,392 | 730.99 |
Levered Free Cash Flow | -24,678 | -9,684 | -15,354 | -140.43 | 10,027 | - |
Unlevered Free Cash Flow | -22,436 | -7,875 | -14,254 | 509.14 | 10,286 | - |
Change in Working Capital | -17,878 | -970.91 | -14,706 | -4,427 | 1,999 | -6,642 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.